Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer.

@article{NiculescuDuvaz2010TrastuzumabEA,
  title={Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer.},
  author={Ion Niculescu-Duvaz},
  journal={Current opinion in molecular therapeutics},
  year={2010},
  volume={12 3},
  pages={350-60}
}
Roche Holding AG, and its subsidiaries Genentech Inc and Chugai Pharmaceutical Co Ltd, are developing trastuzumab emtansine (trastuzumab-DM1) for the treatment of HER2+ metastatic breast cancer. Trastuzumab emtansine is a tumor-activated prodrug resulting from the conjugation of the humanized anti-HER2 mAb trastuzumab, which has been used in the treatment of breast cancer for over 10 years, with ImmunoGen Inc's cytotoxic and antimitotic maytansine derivative DM1. The maytansinoids bind… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

HER2-positive gastric cancer

Gastric Cancer • 2013
View 6 Excerpts
Highly Influenced

HELM Software for Biopolymers.

Journal of chemical information and modeling • 2017

Similar Papers

Loading similar papers…